GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » ROC (Joel Greenblatt) %

Hisamitsu Pharmaceutical Co (TSE:4530) ROC (Joel Greenblatt) % : 30.86% (As of Aug. 2024)


View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Hisamitsu Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Aug. 2024 was 30.86%.

The historical rank and industry rank for Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % or its related term are showing as below:

TSE:4530' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.86   Med: 38.08   Max: 44.61
Current: 26.95

During the past 13 years, Hisamitsu Pharmaceutical Co's highest ROC (Joel Greenblatt) % was 44.61%. The lowest was 17.86%. And the median was 38.08%.

TSE:4530's ROC (Joel Greenblatt) % is ranked better than
74.73% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 9.36 vs TSE:4530: 26.95

Hisamitsu Pharmaceutical Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -7.70% per year.


Hisamitsu Pharmaceutical Co ROC (Joel Greenblatt) % Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co ROC (Joel Greenblatt) % Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.23 17.86 19.00 24.74 27.84

Hisamitsu Pharmaceutical Co Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.53 26.92 13.36 37.22 30.86

Competitive Comparison of Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % falls into.



Hisamitsu Pharmaceutical Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: May. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(42296 + 22719 + 6984) - (11047 + 0 + 43509)
=17443

Working Capital(Q: Aug. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(51878 + 23004 + 9425) - (16876 + 0 + 40656)
=26775

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Hisamitsu Pharmaceutical Co for the quarter that ended in Aug. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Aug. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: May. 2024  Q: Aug. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=24792/( ( (57617 + max(17443, 0)) + (58828 + max(26775, 0)) )/ 2 )
=24792/( ( 75060 + 85603 )/ 2 )
=24792/80331.5
=30.86 %

Note: The EBIT data used here is four times the quarterly (Aug. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hisamitsu Pharmaceutical Co  (TSE:4530) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Hisamitsu Pharmaceutical Co ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hisamitsu Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co Headlines

No Headlines